Actively Recruiting
Evaluation of the Efficacy and Safety of Autologous Fat Injection Into the Intersphincter Space in Fecal Incontinence: a Randomized, Placebo-controlled, Cross-over, Double-blind Trial
Led by Rennes University Hospital · Updated on 2024-09-25
50
Participants Needed
3
Research Sites
262 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Fecal incontinence is frequent and has a significant impact on the quality of life of individuals. Its therapeutic management is based primarily on transit regulation and rehabilitation and secondarily on neuromodulation of the sacral roots. However, this strategy is insufficient in more than one patient out of three. The patient and the clinician are often at a loss and the therapeutic possibilities are limited to the use of evacuating enemas and/or a colostomy. The practice of autologous fat injections was initially developed in plastic surgery. The studies that have evaluated the efficacy of autologous fat injections in fecal incontinence in men are preliminary and old isolated observations. However, they have shown an improvement in episodes of fecal incontinence and in sphincter parameters. In the field of proctology and autologous fat injections, 2 recent small open studies have evaluated the efficacy and morbidity of this therapy in the treatment of anal fistulas related to Crohn's disease. The primary hypothesis of the work is that autografting adipose tissue into the intersphincteric space can decrease episodes of fecal incontinence in patients with severe fecal incontinence due to sphincter failure. The secondary hypotheses are that autograft of adipose tissue in the intersphincter space improves resting anal pressures, is a well-tolerated technique for patients, and may improve their quality of life.
CONDITIONS
Official Title
Evaluation of the Efficacy and Safety of Autologous Fat Injection Into the Intersphincter Space in Fecal Incontinence: a Randomized, Placebo-controlled, Cross-over, Double-blind Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Severe fecal incontinence with at least one episode weekly
- Failed rehabilitation and dietary management
- Failed, contraindicated, or refused sacral root neuromodulation for fecal incontinence
- Women of childbearing age must use effective contraception throughout the study
- Provided free, informed, and written consent
You will not qualify if you...
- Unable or unwilling to undergo follow-up or symptom evaluation
- Contraindication to general anesthesia
- Allergy or contraindication to metronidazole
- Significant pelvic static disorder
- Active anal infection or suppuration
- Anal stenosis
- Externalized rectal prolapse
- Chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Taking anticoagulants or antiaggregants
- History of anal or rectal cancer
- Coagulation disorder or curative anticoagulation
- History of rectal surgery
- History of pelvic radiotherapy
- Previous treatment with inert materials in the past 5 years
- Allergy to lidocaine or contraindication to adrenaline
- Legal protection status, pregnancy, breastfeeding, or minor status
- Concurrent participation in another interventional trial
- Not covered by social security system
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
CHU Angers
Angers, France
Not Yet Recruiting
2
CHU Nantes
Nantes, France
Not Yet Recruiting
3
CHU Rennes
Rennes, France
Actively Recruiting
Research Team
M
Mevel Nicolas
CONTACT
G
Ganivet Anne
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here